Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
Why invest in AVO?
Advanced Oncotherapy: THE INVESTMENT CASE

Advanced Oncotherapy secures £37.4mln of new financing

The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre
Harley Street sign
INVESTMENT OVERVIEW: AVO The Big Picture
The proton therapy system is being installed at a facility in Harley Street, London

Shares of Advanced Oncotherapy PLC (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, shot up 30% after it secured £37.4mln of fresh funding, with £30mln of this coming from a new Chinese investor.

The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre.

READ: Advanced Oncotherapy making significant progress; in stronger position to assess funding options

The cash will come in three distinct tranches. Yantai CIPU Medical Technology, a medical devices firm based in the People’s Republic, is directly investing in Advanced Oncotherapy. It is acquiring £13.5mln in shares at 30p each, giving it a 29.9% stake in the business.

It is also paying £16.5mln for the rights to sell the LIGHT system China, Macau, Taiwan, Hong-Kong and South Korea.

Funding from investors

A further £7.4mln will come from other equity investors who are also buying stock at 30p each, which represents a 10% discount to last night’s closing price.

Chief executive Nicolas Serandour said he was delighted to have concluded a deal that brought in longer-term financing as well as a new, experienced strategic partner.

READ: Advanced Oncotherapy on track with development of first LIGHT system as it checks off another key milestone

"This deal is consistent with our strategy to focus our resources on the technological development of the first LIGHT system and to establish partnerships with those businesses that have a strong track record of market access and a unique expertise in their own geographies,” he added.

“With our long-term financing arrangements now well engaged we can continue to focus on making our unique proton therapy technology available to patients around the world."

The company in its update said work with Metric Capital Partners to conclude a £24mln loan facility continues.

“Terms and conditions are being updated to reflect the developments since the initial announcement of the agreement with Metric in May 2016,” it added.

Shares motor

The shares, up 132% in the last week, advanced 13p to 46p in morning trade. That's an immediate 10p a share profit for investors who backed the latest fundraiser.

LIGHT stands for Linac Image Guided Hadron Technology. The kit is cheaper and smaller than the current units, which are almost prohibitively expensive.

It has the ability to propel protons at the speeds generated by much larger machines.

The proton accelerator used by Advanced Oncotherapy was licensed from CERN, the European Organisation for Nuclear Research, which is currently hunting the ‘God particle’.

Increasing demand for proton therapy

“There is an increasing demand for proton therapy globally, with millions of patients who could potentially benefit from this technology,” said chairman, Dr Michael Sinclair recently.

“While the access to this technology remains scarce, there is a significant unmet medical need the LIGHT system is uniquely suited to provide.

“We are in a prime position to provide a novel and disruptive technology that advances current methods of cancer treatment in the UK and worldwide.

“There is mounting evidence for the clinical superiority of proton therapy over traditional X-ray radiotherapy.

“This evidence will only increase as more proton beam centres are built and more patients are treated. LIGHT's modularity and linear design allow for mass production, shorter manufacturing lead times, easier installation/commissioning and offer both cost and clinical advantages.”

View full AVO profile View Profile

Advanced Oncotherapy Timeline

Related Articles

1-Operation.jpg
January 18 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
Harley Street sign
Thu
The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre
Frosties Box
December 04 2017
The company is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use